Corynebacterium kroppenstedtii

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Corynebacterium kroppenstedtii is a Gram-positive, non-spore-forming, facultatively anaerobic, non-motile, diphtheroidal bacterium. It has been detected in at least 7 gut microbiome compilation studies or metastudies. The DNA G+C content is 62%. Corynebacterium kroppenstedtii is probably a common, although minor, coloniser of the gut. (Collins1998; Bernard2012Bergey)



  • This organism has been recovered from clinical sources (wound, sputum - CCUG) and human faeces. The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread (notes: opportunistic in immunocompromised patients). It is an opportunistic pathogen. A possible gut commensal.
    • GENERAL CHARACTERISTICS (Collins1998); (Bernard2012Bergey);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin;
  • 🧂
  • Salt tolerance:
  • tolerates 10% salt;
  • 🌡
  • Temperature tolerance:
  • grows at 42℃;
  • H+
  • Acid from carbohydrates usually produced:
  • glucose; sucrose;
  • Active enzymes:
  • catalase;
  • ±
  • Strain-dependent active enzymes:
  • esterase C4; esterase lipase C8; Leu arylamidase;
    • SPECIAL FEATURES (Collins1998);
    Character Response
  • ✗
  • Metabolites not produced:
  • propionate;
  • ✓
  • VP test:
  • active
  • ✗
  • Haemolysis:
  • absent
  • ✗
  • Nitrate:
  • not reduced
  • ✗
  • NO3➔NO2:
  • not reduced
  • ✗
  • Pigments:
  • not produced
    • RESPONSE TO ANTIBIOTICS (Collins1998);
    Class Active Resistant
  • Penicillins:
  • penicillin G;
  • Cephalosporins:
  • cefuroxime;
  • Macrolides:
  • erythromycin;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin;

  • Lagier, J.-C., Armougom, F., Million, M., Hugon, P., Pagnier, I., Robert, C., Bittar, F., Fournous, G., Gimenez, G., Maraninchi, M., Trape, J.-F., Koonin, E. V., La Scola, B., & Raoult, D. (2012). Microbial culturomics: paradigm shift in the human gut microbiome study. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 18(12), 1185–1193.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Corynebacteriales Family:  Corynebacteriaceae Genus:  Corynebacterium Gram stain:  + O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Diphtheroidal Pigment:  neg
    Health:  Unknown
    Source:  clinical sources (wound, sputum - CCUG) and human faeces
    DNA G+C(%):  62
    High T(℃):  42(+)
    NaCl >6%:  10(+)
    		Aesculin:  + Urea:  neg Gelatin:  neg Hippurate:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    L-Arabinose:  neg Glucose:  + Ribose:  neg D-Tagatose:  neg Xylose:  neg Lactose:  neg Maltose:  w Melezitose:  neg Sucrose:  + Dextrin:  neg Glycogen:  neg D-Arabitol:  neg Mannitol:  neg Sorbitol:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  + Urease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  neg α-Mannosidase:  neg β-Mannosidase:  neg ArgDH:  neg Chymotrypsin:  neg Trypsin:  neg AlaPheProAA:  neg CystineAA:  neg LeuAA:  d PyrrolidAA:  neg ValAA:  neg AlkalineP:  neg AcidP:  neg Esterase(C4):  d EstLip(C8):  d Lipase(C14):  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Propionate:  neg Pigment:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    penicillin_G:  Sens
    cefuroxime:  Sens
    erythromycin:  Sens
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    vancomycin:  Sens
    clindamycin:  Sens

    References

    SPECIFIC REFERENCES FOR CORYNEBACTERIUM KROPPENSTEDTII
  • Collins1998 - Description of Gemella sanguinis sp. nov., Isolated from Human Clinical Specimens.
  • Bernard2012Bergey - Bergey's manual of systematic bacteriology. Vol. 5, The Actinobacteria. Part A & B. Corynebacteriaceae, Genus I. Corynebacterium
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR CORYNEBACTERIUM KROPPENSTEDTII
  • De2020 - Metagenomic analysis of gut microbiome and resistome of diarrheal fecal samples from Kolkata, India, reveals the core and variable microbiota including signatures of microbial dark matter.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • PerezBrocal2015 - Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects Potential Interactions and Biomarkers
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Yang2020 - Species-Level Analysis of Human Gut Microbiota With Metataxonomics.
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • Added: April 08, 2021